Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

NCT07035002 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07035002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07035002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2024
Completion date
December 31, 2026
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), pd-1, tumor infiltrating lymphocytes